AIkido Labs (AIKI)

Executive Summary

AIkido Labs (formerly AIkido Pharma) is a biotechnology company developing a pipeline of early- to mid-stage small-molecule anti-cancer therapeutics targeting prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). The company also holds an exclusive worldwide license to a broad-spectrum antiviral drug platform from the University of Maryland, Baltimore. With a focus on high-need indications and a dual modality approach (oncology and antivirals), AIkido aims to leverage its expertise to advance novel therapies through preclinical development. The company is privately held and trades over-the-counter under the ticker AIKI. Given its preclinical stage, AIkido represents a high-risk, high-reward opportunity for investors seeking early-stage biotech exposure, with potential value driven by upcoming preclinical data and progress toward IND-enabling studies.

Upcoming Catalysts (preview)

• Q4 2026Preclinical data readout for lead oncology candidate40% success
• Q2 2027IND filing for antiviral platform30% success
• TBDPartnership or licensing deal for pipeline asset20% success